Antibody Production
Rapid recombinant expression from antibody genes ensures lot-to-lot consistency and moves seamlessly from research grade to scale production.
Our in-house-optimized mammalian platform delivers high-efficiency, high-level recombinant antibody expression in HEK293 and CHO cells. Beyond full-length antibodies, it supports Fab, scFv, sdAb/VHH, Fc-fusion proteins, chimeric antibodies, bispecific antibodies and other formats.
Our recombinant antibody expression specialists bring more than fifteen years of project experience, producing high-quality antibodies for IVD raw materials, early drug discovery and preclinical research.
Enquire now →
A mature mammalian cell platform supports stable large-batch production.
A quality system spanning cell line development, process scale-up and purification secures activity, purity and lot-to-lot consistency.
Proven processes and high-expressing cell lines shorten production cycles and keep large-scale supply fast and steady.
Custom process development with production and documentation systems that meet research and preclinical compliance requirements.
Six stages. Projects can start from antibody sequence information (full length or VH/VL), hybridoma cells or cDNA; outputs and acceptance criteria are in the specifications below.
Genes are synthesized and sequence-verified from the antibody sequence
Antibody genes are cloned into high-efficiency mammalian expression vectors
Transient HEK293/CHO expression at high efficiency and level
Affinity chromatography to ≥95% purity
Multi-dimensional QC including SDS-PAGE confirms size and purity
Purified antibody sample and sequencing report delivered
Gene synthesis through purified delivery totals roughly 5–7 weeks. Beyond full-length antibodies, Fab, scFv, sdAb/VHH, Fc-fusion, chimeric and bispecific formats are all produced.
Our in-house-optimized mammalian platform expresses recombinant antibodies efficiently in HEK293 and CHO cells. End-to-end quality control from cell preparation and process scale-up through purification safeguards activity, purity and lot-to-lot consistency for IVD raw materials, early drug discovery and preclinical research.
Deliverables, acceptance criteria and timelines by experimental stage. The staging differs from the process above: the process shows how a project runs, while this table is the acceptance basis written into the contract.
| Stage | Scope | Deliverables | Standards | Timeline |
|---|---|---|---|---|
| Gene synthesis & cloning | Sequence synthesis and vector construction | Sequencing report | Sequence verified | 2–3 weeks |
| Large-scale recombinant antibody expression | Transient expression and purification | Purified antibody sample | Purity ≥95% | 3–4 weeks |
The customer wanted two target antibodies expressed separately and supplied the corresponding plasmids. We expressed both by transient mammalian transfection, purified each supernatant by affinity chromatography, then ran SDS-PAGE and QC on the purified products to confirm expression and purification.
Expressed successfully in the transient system; after affinity chromatography, SDS-PAGE shows an accurate molecular weight and clean bands. The purified product has few impurity bands, a good appearance and purity meeting the delivery standard.
Also expressed stably; after purification SDS-PAGE shows the main band at the right position on a clean background with high purity. A second polish further improved band quality, and the final transparent sample passed QC.
Share the intended application and what you already have in hand. A scientist — not a sales rep — will scope feasibility, suggest the right route and send a quote, usually within one business day.
